Search results for "ORPHAN DRUG|Designated|Treatment of splenic marginal zone lymphoma" in comments (approximate match)
Showing 1 - 4 of 4 results
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Idelalisib is a first-in-class selective inhibitor of adenosine-5'-triphosphate (ATP) binding to PI3Kdelta kinase, resulting in inhibition of the P13K signalling pathway in malignant B cells. The compound is approved for the treatment of several typ...
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Copanlisib, developed by Bayer, is a phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival...
